[HTML][HTML] Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
AR Jazieh, R Al Sudairy, N Abu-Shraie… - Annals of thoracic …, 2013 - journals.lww.com
BACKGROUND: Targeting epidermal growth factor receptors (EGFR) is an innovative
approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation …
approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation …
[HTML][HTML] Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
F Hirai, M Edagawa, S Shimamatsu… - Oncology …, 2017 - spandidos-publications.com
Erlotinib is one of the treatment choices for patients with advanced non‑small cell lung
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - Wiley Online Library
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim …
R Rosell, R Gervais, A Vergnenegre… - Journal of clinical …, 2011 - ascopubs.org
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
B Piperdi, R Perez-Soler - Drugs, 2012 - Springer
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) …
8023 Background: The purpose of the study was to evaluate the efficacy of erlotinib and the
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
T Kobayashi, T Koizumi, T Agatsuma, M Yasuo… - Cancer chemotherapy …, 2012 - Springer
Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …
T Payen, J Trédaniel, L Moreau, S Larivé… - … Medicine and Research, 2021 - Elsevier
Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …